Amarin Pharma, Inc. et al v. Roxane Laboratories, Inc. et.al,

Filing 112

ORDER granting ECF No. 111 Proposed Discovery Plan/Scheduling Order. Signed by Magistrate Judge Nancy J. Koppe on 1/30/2018. (Copies have been distributed pursuant to the NEF - KW)

1
2
3
4
5
6
7
8
9
10
11
12

Nicholas J. Santoro (Nev. Bar No. 532)
Jason D. Smith (Nev. Bar No. 9691)
SANTORO WHITMIRE, LTD.
10100 W. Charleston Blvd., Suite 250
Las Vegas, NV 89135
Telephone: [phone]
Facsimile: [phone]
E-mail: [e-mail],
[e-mail]
Christopher N. Sipes (pro hac vice)
Einar Stole (pro hac vice)
Michael N. Kennedy (pro hac vice)
Megan P. Keane (pro hac vice)
COVINGTON & BURLING LLP
One CityCenter, 850 Tenth Street, NW
Washington, DC 20001
Telephone: [phone]
Facsimile: [phone]
E-mail: [e-mail], [e-mail],
[e-mail], [e-mail]

13
14

Attorneys for Plaintiffs Amarin Pharma, Inc. and
Amarin Pharmaceuticals Ireland Limited

15
UNITED STATES DISTRICT COURT
DISTRICT OF NEVADA

16
17
18
19

AMARIN PHARMA, INC. and AMARIN
PHARMACEUTICALS IRELAND LIMITED,
Plaintiffs,

20
21

v.

22

TEVA PHARMACEUTICALS USA, INC.,

23
24
25
26
27
28

Defendant.

Case No.: 2:16-cv-02525-MMD-NJK
(Consolidated with 2:16-cv-02562-MMDNJK, 2:16-cv-02658-MMD-NJK, and
2:17-cv-02641-MMD-NJK)
STIPULATED DISCOVERY PLAN AND
SCHEDULING ORDER
SPECIAL SCHEDULING REVIEW
REQUESTED

1

I.

2

LR 26-1 STATEMENT REGARDING SPECIAL SCHEDULING REVIEW
In this case, Plaintiffs Amarin Pharma, Inc. and Amarin Pharmaceutical Ireland Limited

3

(collectively, “Plaintiffs” or “Amarin”) assert that Defendant Teva Pharmaceuticals USA, Inc.

4

(“Teva”) has infringed twelve of Amarin’s patents based on Teva’s filing an Abbreviated New

5

Drug Application (“ANDA”) with the U.S. Food and Drug Administration that seeks approval to

6

market a generic version of Amarin’s Vascepa® 500 mg product. In light of the similarity in the

7

factual and legal issues, the Court has consolidated this case with three others, see ECF No. 91,

8

in which Amarin asserts that Teva and two other defendant groups each infringed fourteen

9

Amarin patents by filing an ANDA seeking approval to market generic versions of Amarin’s

10

Vascepa® 1 g product, specifically Civ. A. Nos. 2:16-cv-02525, 2:16-cv-02562, 2:16-cv-02658

11

(the “1 g action”). The Court has already entered a schedule in the 1 g action. See ECF No. 60.

12

In light of the consolidation of this case with the 1 g action and the similarities in legal

13

and factual issues among the cases, the parties propose a case schedule that will ultimately keep

14

all four cases on the same schedule. With the few exceptions identified below, the parties

15

respectfully propose that the Court align the deadlines in this case with those already set in the

16

1 g action. The parties agree that the proposed discovery period is appropriate given the

17

complexity of this patent infringement action. Moreover, the 30-month stay pertaining to this

18

case does not expire until on or about February 29, 20201 and the proposed schedule provides

19

sufficient time for the case to be resolved in advance of expiration of the stay. Consolidating the

20

two case schedules will also streamline the matter and conserve both party and court resources.

21

II.

THE PARTIES’ PROPOSED DISCOVERY SCHEDULE

22

The parties stipulate and agree that, with the exception of the dates specified below, the

23

deadlines already imposed in the consolidated 1 g action, see ECF No. 60, as modified by ECF

24

Nos. 88, 92, 103, 107, 110, should govern in this case.

25
26
27
28

1

Amarin believes the expiration date is on or about March 1, 2020; Teva believes the expiration
date is on or about Feb. 29, 2020.

-2-

1

Events

Proposed Date

2

Initial Disclosures & Scheduling Order

January 29, 2018

3

Asserted Claims and Supplemental
Infringement Contentions

February 16, 2018

4

Supplemental Noninfringement, Invalidity,
and Unenforceability Contentions

5

Responses to Supplemental
Noninfringement, Invalidity, and
Unenforceability Contentions

6
7

March 16, 2018
April 6, 2018

8
9

III.

(1)

10
11

ADDITIONAL INFORMATION UNDER LR 26-1(b) AND FED. R. CIV. P. 26(f)
Initial Disclosures: The parties agree to serve initial disclosure statements

pursuant to Fed. R. Civ. P. 26(a)(1) on January 29, 2018.
(2)

12

Subjects of Discovery: The parties agree that all matters within the scope of Fed.

13

R. Civ. P. 26 will be subjects of discovery (without prejudice to a party’s right to object to

14

discovery or seek a protective order). The parties propose conducting fact discovery followed by

15

expert discovery.

16

(3)

17

in the 1 g action, ECF No. 69, will also apply to this case.
(4)

18
19

E-Discovery: The parties agree that the Discovery Confidentiality Order entered

Privileged Material: The parties agree that the Discovery Confidentiality Order

entered in the 1 g action, ECF No. 69, will also apply to this case.
(5)

20

Discovery Limitations: The parties agree that the discovery limitations in the

21

1 g action will also apply to this case, except that Teva may serve up to 5 additional

22

interrogatories specific to this case.
(6)

23
24

Other Orders: The parties agree that the Discovery Confidentiality Order

entered in the 1 g action, ECF No. 69, will also apply to this case.
(7)

25

Fed. R. Civ. P. 26(a)(3) Disclosures: The parties agree that the disclosures

26

required by Fed. R. Civ. P. 26(a)(3) and any objections thereof shall be included in the pretrial

27

order.

28

-3-

1
2
3

(8)

Alternative Dispute Resolution: The parties certify that they met and conferred

about the possibility of using alternative dispute resolution processes.
(9)

Alternative Forms of Case Disposition: The parties certify that they considered

4

consenting to trial by a magistrate judge under 28 U.S.C. § 636(c) and Fed. R. Civ. P. 73 and the

5

use of the Short Trial Program (General Order 2013-01).

6
7

(10)

Email Service: The parties agree to service of all documents by email pursuant

to Fed. R. Civ. P. 5(b)(2)(E).

8
9
10
11
12
13
14
15
16
17
18
19

Dated: January 29, 2018

Dated: January 29, 2018

/s/ Jason D. Smith
Nicholas J. Santoro (Nev. Bar No. 532)
Jason D. Smith (Nev. Bar No. 9691)
SANTORO WHITMIRE, LTD.
10100 W. Charleston Blvd., Suite 250
Las Vegas, NV 89135
Tel.: [phone] / Fax: [phone]
Email: [e-mail],
[e-mail]

/s/ Chandrika Vira
John P. Desmond (Nev. Bar No. 5618)
Brian R. Irvine (Nev. Bar No. 7758)
DICKINSON WRIGHT PLLC
100 West Liberty St., Suite 940
Reno, NV 89501
Tel.: [phone] / Fax: [phone]
Email: [e-mail],
[e-mail]

Christopher N. Sipes (pro hac vice)
Einar Stole (pro hac vice)
Michael N. Kennedy (pro hac vice)
Megan P. Keane (pro hac vice)
COVINGTON & BURLING LLP
One CityCenter, 850 Tenth Street, NW
Washington, DC 20001
Tel.: [phone] / Fax: [phone]
Email: [e-mail], [e-mail],
[e-mail], [e-mail]

J.C. Rozendaal (pro hac vice)
Michael E. Joffre (pro hac vice)
Chandrika Vira (pro hac vice)
STERNE, KESSLER, GOLDSTEIN & FOX
1100 New York Ave., NW
Washington, DC 20005
Tel.: [phone] / Fax: [phone]
Email: [e-mail],
[e-mail], [e-mail]

20
21

Counsel for Plaintiffs Amarin Pharma, Inc.
and Amarin Pharmaceuticals Ireland
Limited

Counsel for Defendant Teva Pharmaceuticals
USA, Inc.

22
23

IT IS SO ORDERED.

24
25
26
27
28

______________________________________
UNITED STATES MAGISTRATE JUDGE
January 30, 2018
DATED:______________________________
-4-